Lux Biosciences, Inc., a biotechnology company, develops medications to treat ophthalmic diseases. Its products include LX201, a silicone matrix ocular implant that enables the release of cyclosporine A to the eye for one year; Luveniq, an oral form of calcineurin inhibitor voclosporin; LX212, a bioerodible polymer implant that contains voclosporin; and LX214, a topical mixed nanomicellar formulation of voclosporin therapy for dry eyes. The company was founded in 2005 and is based in Jersey City, New Jersey.

Recent Milestones
edit

Lux Biosciences received $50M in Series B funding. (10/1/09)

Posted 10/19/09 at 5:47pm via venturebeat.com
Lux Biosciences added Eddy Anglade as Co-Founder and Chief Medical Officer .

Posted 10/19/09 at 5:47pm
Lux Biosciences added David Schnell as Director.

Posted 4/17/13 at 1:35am
Lux Biosciences added Sidney L. Weiss as Co-Founder and Vice President of Program Management .

Posted 10/19/09 at 5:47pm
Lux Biosciences added Ulrich Grau as Co-Founder.

Posted 10/19/09 at 5:47pm
Lux Biosciences added Dean J. Mitchell as CEO .

Posted 6/14/13 at 3:11am